The debate highlighted that G2019S shows elevated baseline RAB10 phosphorylation, but it's unclear whether this represents true signal amplification during lysosomal swelling or just a higher activity floor. This distinction is crucial for understanding disease mechanisms and therapeutic targeting.
Source: Debate session sess_SDA-2026-04-16-gap-pubmed-20260410-170027-a1e5f867_20260416-135352 (Analysis: SDA-2026-04-16-gap-pubmed-20260410-170027-a1e5f867)
A credible refinement is that any true amplification is not universal across cell types, but emerges most strongly in professional phagocytes with high endogenous LRRK2 activity, chronic cargo load, and active endolysosomal remodeling. This would reconcile modest blood-cell baseline effects with larger functional consequences in microglia/macrophages relevant to inflammatory and trafficking phenotypes.
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
flowchart TD
A["LRRK2 G2019S Mutation Kinase Hyperactivity"]
B["RAB10 Activation GTP-bound State"]
C["RAB10 Phosphorylation T73 on ExoCycling Machinery"]
D["GLUT4 Translocation Endosomal Recycling Defect"]
E["ER-to-Golgi Transport Vesicle Cargo Delay"]
F["Synaptic Vesicle Pool Reduced Recycling Rate"]
G["Neuronal Homeostasis Impaired Lysosomal Trafficking"]
H["alpha-Synuclein Aggregation PD-Relevant Pathology"]
A --> B
B --> C
C --> D
D --> E
E --> F
F --> G
C --> G
G --> H
style A fill:#7b1fa2,stroke:#ce93d8,color:#ce93d8
style H fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
9 citations9 with PMID5 mediumValidation: 0%7 supporting / 2 opposing
✓For(7)
5
No opposing evidence
(2)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
5
2
2
MECH 5CLIN 2GENE 2EPID 0
Claim
Stance
Category
Source
Strength ↕
Year ↕
Quality ↕
PMIDs
Abstract
Microglia rescue neurons from aggregate-induced ne…
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-24 | View Analysis
🧬TheoristProposes novel mechanisms and generates creative hypotheses▼
Title: `G2019S raises the LRRK2 kinase floor more than the swelling gain`
Mechanism: G2019S may primarily increase constitutive catalytic output, producing higher baseline pRab10/pRab12 without materially changing the slope of the lysosomal volume-response curve. In this model, swelling still activates the same upstream lysosomal recruitment/activation circuit, but mutant cells start from a higher baseline rather than showing stronger fold-amplification.
🔍SkepticIdentifies weaknesses, alternative explanations, and methodological concerns▼
Skeptical Read
The main weakness across all six is the same: most cited evidence shows that mutant `LRRK2` can elevate phospho-Rab output or alter lysosomal remodeling, but it does not cleanly separate `baseline offset` from `stimulus gain`. Much of the literature uses overexpression, artificial membrane targeting, `LLOME` or lysosomotropic stress, PBMCs, or macrophage-like cells. Those systems are useful for mechanism discovery, but they are not decisive for the specific question “does G2019S amplify volume sensing, or just raise the floor?”
**`G2019S raises the kinase floor more
🎯Domain ExpertAssesses practical feasibility, druggability, and clinical translation▼
As of April 24, 2026, the hypotheses that most credibly survive are:
#1 Higher baseline kinase activity more than higher swelling gain
#4 Amplification is context-dependent and strongest in microglia/macrophages
#5 `pRab12` may be the better translational biomarker under chronic lysosomal stress
#6 A downstream `LRRK2-Rab10/JIP4` lysosomal stress to α-syn release loop is plausible
#2 LYTL/JIP4 remodeling is a useful mechanistic phenotype, but not yet a primary therapeutic thesis
#3 phosphatase buffering survives as an assay-interpretation modifier,
⚖SynthesizerIntegrates perspectives and produces final ranked assessments▼
{ "ranked_hypotheses": [ { "title": "G2019S primarily raises baseline LRRK2 kinase activity rather than amplifying lysosomal swelling gain", "description": "The most supported model is that pathogenic G2019S shifts the basal catalytic set-point upward, producing higher baseline phospho-Rab output while leaving the core lysosomal volume-sensing response architecture largely intact. In this view, mutant cells begin from a higher activity floor, and the key experimental discriminator is whether baseline-normalized EC50, slope, or Emax materially increase during graded swelling."
IF LRRK2 G2019S primary microglia and CD14+ peripheral monocytes are treated with LRRK2 kinase inhibitor MLi-2 (100 nM) for 24 hours, THEN pT73 RAB10 phosphorylation will be suppressed by >50% in microglia but <25% in monocytes, measured by quantitative phospho-SILAC proteomics.
pendingconf: 0.45
Expected outcome: Microglia will show significantly greater RAB10 phosphorylation suppression than monocytes following LRRK2 inhibition, confirming cell-type-specific amplification.
Falsified by: If RAB10 pT73 suppression is equivalent (<10% difference) or greater in monocytes compared to microglia, context-dependent amplification is not supported.
Method: Primary cultures from LRRK2 G2019S knock-in mice (B6.129S7-Lrrk2<tm1.1Arte>) and matched human CD14+ monocytes from G2019S carrier and non-carrier donors (n≥4 per group), 100 nM MLi-2 treatment for 24h, phospho-RAB10 ELISA and Western blot quantification.
IF LRRK2 G2019S microglia are stimulated with aggregated α-synuclein (1 µg/mL) for 48 hours, THEN RAB10-GTP loading will increase >2-fold relative to vehicle control, while peritoneal macrophages from the same mice will show <1.5-fold increase.
pendingconf: 0.42
Expected outcome: Microglia will demonstrate stronger RAB10 activation than peritoneal macrophages in response to neurodegeneration-relevant cargo load, confirming professional phagocyte context specificity.
Falsified by: If peritoneal macrophages show equal or greater RAB10-GTP induction (>1.8-fold) compared to microglia, the hypothesis that amplification is strongest in brain-resident microglia is disproven.
Method: Age-matched LRRK2 G2019S knock-in mice (8-12 weeks, n=6 per group), primary microglia culture vs thioglycolate-elicited peritoneal macrophages, 1 µg/mL pre-formed α-synuclein fibrils (PFFs) for 48h, active RAB10 pull-down assay (RAB10 GTPase activation kit) with densitometry.